Implications of rarity of chromosome 17 polysomy in breast cancer

The Lancet Oncology

Volumn 12, Issue 12, 2011, Pages 1087-1089

  Moelans, Cathy B ^a   Reis Filho, Jorge S ^b   Van Diest, Paul J ^a  

^a UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^b INSTITUTE OF CANCER RESEARCH   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTHRACYCLINE; EPIDERMAL GROWTH FACTOR RECEPTOR 2; LAPATINIB; TRASTUZUMAB;

BREAST CANCER; CANCER CHEMOTHERAPY; CENTROMERE; CHROMOGENIC IN SITU HYBRIDIZATION; CHROMOSOME 17; CHROMOSOME 17 POLYSOMY; CHROMOSOME 17P; CHROMOSOME 17Q; DRUG RESPONSE; FLUORESCENCE IN SITU HYBRIDIZATION; GENE; GENE AMPLIFICATION; GENE DOSAGE; HER2 GENE; HUMAN; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION; LETTER; NUMERICAL CHROMOSOME ABERRATION; ONCOGENE NEU; PATIENT SELECTION; PERSONALIZED MEDICINE; PRIORITY JOURNAL; SILVER IN SITU HYBRIDIZATION;

BREAST NEOPLASMS; CENTROMERE; CHROMOSOME ABERRATIONS; CHROMOSOMES, HUMAN, PAIR 17; FEMALE; GENE AMPLIFICATION; GENE DOSAGE; GENETIC TESTING; HUMANS; IMMUNOHISTOCHEMISTRY; INDIVIDUALIZED MEDICINE; PREDICTIVE VALUE OF TESTS; PROGNOSIS; RECEPTOR, ERBB-2;

EID: 81255190713     PISSN: 14702045     EISSN: 14745488     Source Type: Journal    
DOI: 10.1016/S1470-2045(11)70234-0     Document Type: Letter

References (11)

1. Wolff AC, Hammond ME, Schwartz JN, et al. American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. Arch Pathol Lab Med 2007, 131:18-43.
2. Hyun CL, Lee HE, Kim KS, et al. The effect of chromosome 17 polysomy on HER-2/neu status in breast cancer. J Clin Pathol 2008, 61:317-321.
3. Yeh IT, Martin MA, Robetorye RS, et al. Clinical validation of an array CGH test for HER2 status in breast cancer reveals that polysomy 17 is a rare event. Mod Pathol 2009, 22:1169-1175.
4. Marchiò C, Lambros MB, Gugliotta P, et al. Does chromosome 17 centromere copy number predict polysomy in breast cancer? A fluorescence in situ hybridization and microarray-based CGH analysis. J Pathol 2009, 219:16-24.
5. Gunn S, Yeh IT, Lytvak I, et al. Clinical array-based karyotyping of breast cancer with equivocal HER2 status resolves gene copy number and reveals chromosome 17 complexity. BMC Cancer 2010, 10:396.
6. Staaf J, Jönsson G, Ringnér M, et al. High-resolution genomic and expression analyses of copy number alterations in HER2-amplified breast cancer. Breast Cancer Res 2010, 12:R25.
7. Varga Z, Tubbs RR, Wang Z, et al. Co-amplification of the HER2 gene and chromosome 17 centromere: a potential diagnostic pitfall in HER2 testing in breast cancer. Breast Cancer Res Treat 2011, published online June 23. 10.1007/s10549-011-1642-8.
8. Moelans CB, de Weger RA, van Diest PJ Absence of chromosome 17 polysomy in breast cancer: analysis by CEP17 chromogenic in situ hybridization and multiplex ligation-dependent probe amplification. Breast Cancer Res Treat 2010, 120:1-7.
9. Viale G Be precise! The need to consider the mechanisms for CEP17 copy number changes in breast cancer. J Pathol 2009, 219:1-2.
10. Paik S, Kim C, Wolmark N HER2 status and benefit from adjuvant trastuzumab in breast cancer. N Engl J Med 2008, 358:1409-1411.
11. Bartlett JM, Desmedt C, Munro A, et al. Chromosome 17 polysomy: a unifying hypothesis underlying benefit from adjuvant anthracyclines?. Cancer Res 2009, 69(suppl):11.